These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 38481949)

  • 1. Progress and prospect of ASCT combined with CAR-T therapy in the treatment of multiple myeloma.
    Yuan S; Chen Y; Liu H
    Ther Adv Hematol; 2024; 15():20406207241237594. PubMed ID: 38481949
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma.
    Garfall AL; Stadtmauer EA; Hwang WT; Lacey SF; Melenhorst JJ; Krevvata M; Carroll MP; Matsui WH; Wang Q; Dhodapkar MV; Dhodapkar K; Das R; Vogl DT; Weiss BM; Cohen AD; Mangan PA; Ayers EC; Nunez-Cruz S; Kulikovskaya I; Davis MM; Lamontagne A; Dengel K; Kerr ND; Young RM; Siegel DL; Levine BL; Milone MC; Maus MV; June CH
    JCI Insight; 2018 Apr; 3(8):. PubMed ID: 29669947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autologous Stem Cell Transplantation for Myeloma: Cytoreduction or an Immunotherapy?
    Minnie SA; Hill GR
    Front Immunol; 2021; 12():651288. PubMed ID: 33777050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy of multiple myeloma.
    Minnie SA; Hill GR
    J Clin Invest; 2020 Apr; 130(4):1565-1575. PubMed ID: 32149732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of the bone marrow microenvironment in multiple myeloma treatment using CAR-T therapy.
    Yao H; Cheng L; Chen D; Zhang Q; Qiu L; Ren SH; Dou BT; Wang H; Huang J; Fan FY
    Expert Rev Anticancer Ther; 2023; 23(8):807-815. PubMed ID: 37343305
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resource utilization for chimeric antigen receptor T cell therapy versus autologous hematopoietic cell transplantation in patients with B cell lymphoma.
    Ring A; Grob B; Aerts E; Ritter K; Volbracht J; Schär B; Greiling M; Müller AMS
    Ann Hematol; 2022 Aug; 101(8):1755-1767. PubMed ID: 35759026
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD19/CD22 Chimeric Antigen Receptor T Cell Cocktail Therapy following Autologous Transplantation in Patients with Relapsed/Refractory Aggressive B Cell Lymphomas.
    Cao Y; Xiao Y; Wang N; Wang G; Huang L; Hong Z; Meng L; Zhou X; Wang J; Yang Y; Xu H; Zhang S; Xiao M; Chen L; Zheng M; Li C; Mao X; Gu C; Zhang T; Zhang Y; Zhou J
    Transplant Cell Ther; 2021 Nov; 27(11):910.e1-910.e11. PubMed ID: 34425260
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparation of CART19 and autologous stem-cell transplantation for refractory/relapsed non-Hodgkin's lymphoma.
    Li C; Zhang Y; Zhang C; Chen J; Lou X; Chen X; Kang L; Xu N; Li M; Tan J; Sun X; Zhou J; Yang Z; Zong X; Wang P; Xu T; Qu C; Huang H; Jin Z; Yu L; Wu D
    JCI Insight; 2019 Jul; 5(17):. PubMed ID: 31335321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current advances in chimeric antigen receptor T-cell therapy for refractory/relapsed multiple myeloma.
    Huang H; Wu HW; Hu YX
    J Zhejiang Univ Sci B; 2020 Jan.; 21(1):29-41. PubMed ID: 31898440
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Autologous Hematopoietic Stem Cells Transplantation Combination-Based Chimeric Antigen Receptor T-Cell Therapy Improves Outcomes of Relapsed/Refractory Central Nervous System B-Cell Lymphoma.
    Xue F; Zheng P; Liu R; Feng S; Guo Y; Shi H; Liu H; Deng B; Xu T; Ke X; Hu K
    J Oncol; 2022; 2022():2900310. PubMed ID: 36483984
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allogeneic Anti-BCMA CAR T Cells Are Superior to Multiple Myeloma-derived CAR T Cells in Preclinical Studies and May Be Combined with Gamma Secretase Inhibitors.
    Metelo AM; Jozwik A; Luong LA; Dominey-Foy D; Graham C; Attwood C; Inam S; Dunlop A; Sanchez K; Cuthill K; Rice C; Streetly M; Bentley T; Boldajipour B; Sommer C; Sasu B; Benjamin R
    Cancer Res Commun; 2022 Mar; 2(3):158-171. PubMed ID: 36874402
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune Signatures Associated With Clonal Isotype Switch After Autologous Stem Cell Transplantation for Multiple Myeloma.
    Ye R; Kundrapu S; Gerson SL; Driscoll JJ; Beck R; Ali N; Landgren O; VanHeeckeren W; Luo G; Kroger N; Caimi P; De Lima M; Malek E
    Clin Lymphoma Myeloma Leuk; 2019 May; 19(5):e213-e220. PubMed ID: 30878316
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Comparison of single infusion of anti-BCMA versus combined infusion of anti-CD19 chimeric antigen receptor T cells for immune reconstruction in relapsed/refractory multiple myeloma].
    Ge J; Zhao TT; Wan CY; Xia JY; Guo SY; Yu MX; Chen J; Wang Y; Xu KL; Li ZY
    Zhonghua Xue Ye Xue Za Zhi; 2021 Sep; 42(9):733-738. PubMed ID: 34753227
    [No Abstract]   [Full Text] [Related]  

  • 14. Immune Reconstitution following High-Dose Chemotherapy and Autologous Stem Cell Transplantation with or without Pembrolizumab Maintenance Therapy in Patients with Lymphoma.
    Merryman RW; Redd R; Jeter E; Wong JL; McHugh K; Reynolds C; Nazzaro M; Varden A; Brown JR; Crombie JL; Davids MS; Fisher DC; Jacobsen E; Jacobson CA; Kim AI; LaCasce AS; Ng SY; Odejide OO; Parry EM; Dahi PB; Nieto Y; Joyce RM; Chen YB; Herrera AF; Armand P; Ritz J
    Transplant Cell Ther; 2022 Jan; 28(1):32.e1-32.e10. PubMed ID: 34670169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of Salvage Treatments in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Including Chimeric Antigen Receptor T-Cell Therapy: A Systematic Review and Meta-Analysis.
    Kim J; Cho J; Yoon SE; Kim WS; Kim SJ
    Cancer Res Treat; 2023 Jul; 55(3):1031-1047. PubMed ID: 36915243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Are Autologous Stem Cell Transplants Still Required to Treat Myeloma in the Era of Novel Therapies? A Review from the Chronic Malignancies Working Party of the EBMT.
    Garderet L; Morris C; Beksac M; Gahrton G; Schönland S; Yakoub-Agha I; Hayden PJ
    Biol Blood Marrow Transplant; 2020 Sep; 26(9):1559-1566. PubMed ID: 32417491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic impact of natural killer cell recovery on minimal residual disease after autologous stem cell transplantation in multiple myeloma.
    Keruakous AR; Asch A; Aljumaily R; Zhao D; Yuen C
    Transpl Immunol; 2022 Apr; 71():101544. PubMed ID: 35093506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment Strategy for Multiple Myeloma to Improve Immunological Environment and Maintain MRD Negativity.
    Suzuki K; Nishiwaki K; Yano S
    Cancers (Basel); 2021 Sep; 13(19):. PubMed ID: 34638353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T-cell Exhaustion in Multiple Myeloma Relapse after Autotransplant: Optimal Timing of Immunotherapy.
    Chung DJ; Pronschinske KB; Shyer JA; Sharma S; Leung S; Curran SA; Lesokhin AM; Devlin SM; Giralt SA; Young JW
    Cancer Immunol Res; 2016 Jan; 4(1):61-71. PubMed ID: 26464015
    [TBL] [Abstract][Full Text] [Related]  

  • 20. T cells isolated from G-CSF-treated multiple myeloma patients are suitable for the generation of BCMA-directed CAR-T cells.
    Battram AM; Oliver-Caldés A; Suárez-Lledó M; Lozano M; Bosch I Crespo M; Martínez-Cibrián N; Cid J; Moreno DF; Rodríguez-Lobato LG; Urbano-Ispizua A; Fernández de Larrea C
    Mol Ther Methods Clin Dev; 2022 Sep; 26():207-223. PubMed ID: 35859694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.